Education
About Us
Working with TipRanks
Follow Us
Alvotech (ALVO)
NASDAQ:ALVO
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
>-0.01Last Year’s EPS
0.14Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 36.40%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Positive
The call presented a strong financial performance with raised revenue guidance and successful product launches, despite some challenges like strong price competition and potential tariff impacts.Company Guidance
During the Alvotech Q1 2025 earnings call, the company provided guidance by revising its full-year financial projections upward, reflecting strong performance and strategic developments. The top-line revenue guidance was increased to a range of $600 million to $700 million, while the adjusted EBITDA guidance was raised to $200 million to $280 million. Alvotech reported a $110 million increase in product revenues for the first quarter, driven by successful launches of biosimilars to Humira and Stelara. The company also achieved a positive adjusted EBITDA of $21 million and expects to be free cash flow positive in 2025. Alvotech plans to launch three new biosimilars by Q4 2025, contributing further to revenue diversification. The guidance reflects the company's robust pipeline, strategic partnerships, and the anticipated growth in biosimilar market share, particularly in the U.S. market.Increased Revenue Guidance
Top line revenue guidance for 2025 is raised to $600 million to $700 million, and adjusted EBITDA guidance is raised to $200 million to $280 million.
Strong Financial Performance
Fourth consecutive quarter of positive adjusted EBITDA and operating profits with triple-digit increases in both product revenues and total revenues compared to the same quarter in the previous year.
Stelara Biosimilar Success
Successful launch of Stelara biosimilar in the U.S. and other markets, with a significant market share and recent FDA approval for interchangeability.
Product Pipeline Expansion
Three biosimilar filings under review in major markets, expected to launch by Q4 2025, expanding to six marketed biosimilars by early 2026.
Positive Cash Flow
Generated $17 million of positive cash flows from operations in Q1, expecting to be free cash flow positive in 2025.
ALVO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALVO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $7.94 | $9.38 | +18.14% |
Mar 26, 2025 | $11.55 | $10.36 | -10.30% |
Nov 13, 2024 | $11.93 | $12.07 | +1.17% |
Aug 15, 2024 | $11.93 | $12.97 | +8.72% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Alvotech (ALVO) report earnings?
Alvotech (ALVO) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Alvotech (ALVO) earnings time?
Alvotech (ALVO) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALVO EPS forecast?
ALVO EPS forecast for the fiscal quarter 2025 (Q2) is >-0.01.